ten Cate H, et al. - Experts explored if prothrombin time (PT) monitoring would improve the benefit-risk profile of rivaroxaban in venous thromboembolism patients. They also investigated the stability of PT values over time and the impact of clinical variables on PT values. They found that peak and trough prothrombin times were stable over time and did not correlate with recurrent thrombosis or major bleeding in 3,797 rivaroxaban-treated patients. In patients with deep vein thrombosis or pulmonary embolism, PT monitoring was unlikely to improve the benefit-risk profile of rivaroxaban.